COPYRIGHT© 2018 吉林紫鑫药业股份有限公司
Announcement of Jilin Zixin Pharmaceutical Co., Ltd. on the establishment of a wholly-owned Sun Company
Stock code: 002118 Securities abbreviation: Zixin Pharmaceutical Announcement No.: 2013-049
Jilin Zixin Pharmaceutical Co., Ltd.
Announcement on the establishment of a wholly-owned Sun Company
The company and all members of the board of directors guarantee that the content of the information disclosure is true, accurate and complete, and there are no false records, misleading statements or major omissions.
I. Overview of foreign investment
Jilin Zixin Pharmaceutical Co., Ltd. (hereinafter referred to as “the company”) enhances the company's core competitiveness in this field in order to consolidate the strong development of the gene sequencing project and its leading position in the industry. The company agreed that Jilin Zhongke Zixin Technology Co., Ltd. (hereinafter referred to as “Zhongke Zixin”), a wholly-owned subsidiary of the company, set up a wholly-owned subsidiary Beijing Zhongke Zixin Technology Co., Ltd. in Beijing with its own capital of 2 million yuan (below) Referred to as "Beijing Zhongke Zixin").
On December 20, 2013, the company held the ninth meeting of the fifth board of directors. The meeting reviewed and approved the “Proposal on Establishing a Full-Capital Sun Company” with the result of a vote of 7 votes, 0 votes against, and 0 abstentions.
The establishment of Beijing Zhongke Zixin is not a related party transaction. According to the provisions of the Articles of Association, the foreign investment matters belong to the decision-making authority of the company's board of directors and need not be submitted to the shareholders' meeting for deliberation.
Second, the introduction of investment entities
Jilin Zhongke Zixin Technology Co., Ltd.
Place of registration: No. 137, Dongtou Road, Nanguan District, Changchun City, Jilin Province
Legal representative: Yin Jinlong
Registered capital: 20 million yuan
Business scope: production and sales of genetic sequencers, reagents and test kits for genetic sequencers; research and development of new drugs, health foods and foods, chemical raw materials, ginseng and related products; technology transfer, technical consultation, and transfer of results.
Third, the basic situation of investment targets
Registered Name: Beijing Zhongke Zixin Technology Co., Ltd.
Place of registration: Room 608, 6th Floor, Building 3, No. 88, Science and Technology Development Zone, Beijing Economic and Technological Development Zone
Legal representative: Yin Jinlong
Registered capital: 2 million yuan
Business scope: research and development of genetic sequencers, reagents and test kits for gene sequencers; research and development of new drugs, health foods and foods.
The above business scope is ultimately subject to the business license approved by the administrative department for industry and commerce.
Fourth, the purpose of foreign investment, existing risks and impact on the company
1. The purpose of foreign investment and the impact on the company
The establishment of Sun Company in Beijing is conducive to the company's development of technology related to genetic sequencing projects; research and development of new drugs, health foods and food to ensure the efficiency of research and development, in line with the company's long-term development strategy.
2, the risk of existence
There are mainly risks in the operation and management of Beijing Zhongke Zixin. The company will implement and implement the various management systems, such as R&D management, financial management and personnel management, to the Sun Company, and promote the stable and rapid development of the company.
V. Documents for reference
Resolution of the Ninth Meeting of the Fifth Board of Directors
Jilin Zixin Pharmaceutical Co., Ltd. Board of Directors
December 21, 2013